Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Peginterferon Ξ±-2b plus an anti-PD-1
The First People's Hospital of Lianyungang
Advanced Solid Tumors
1 trial -
Percutaneous transhepatic biliary stenting with conventional linear ^125^I seeds strand
The First People's Hospital of Lianyungang
Malignant Obstructive Jaundice
1 trial -
Personalized mRNA Tumor Vaccine
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
Prebiotic Fiber Supplement + loperamide hydrochloride capsule
The First People's Hospital of Lianyungang
Chemotherapy-related Diarrhea
1 trial -
Prediction Model Arm
The First People's Hospital of Lianyungang
Lung Cancer Screening
1 trial -
Prediction of intraoperative hypothermia risk
The First People's Hospital of Lianyungang
Intraoperative Hypothermia
1 trial -
Prednisolone
The First People's Hospital of Lianyungang
HIV (Human Immunodeficiency Virus)
1 trial -
Prostate biopsy guided by PSMA PET/CT
The First People's Hospital of Lianyungang
PSMA PET/CT
1 trial -
Protocol-based management of perioperative antithrombotic therapy
The First People's Hospital of Lianyungang
Antithrombotic Therapy
1 trial -
Pueraria lobata radix
The First People's Hospital of Lianyungang
Type 2 Diabetes Mellitus
1 trial -
Qingre Huashi Granules combined the modified dual therapy
The First People's Hospital of Lianyungang
Helicobacter Pylori Infection
1 trial -
R-CDOP
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma
1 trial -
RB001
The First People's Hospital of Lianyungang
Phelan-McDermid Syndrome
1 trial -
Regional lymph node radiotherapy (RNI) including the axilla
The First People's Hospital of Lianyungang
Axillary Lymph Node Dissection
1 trial -
Regorafenib and Sintilimab in combination with electroacupuncture
The First People's Hospital of Lianyungang
Colorectal Cancer Metastatic
1 trial -
Remimazolam
The First People's Hospital of Lianyungang
Sedation and Analgesia
1 trial -
Remimazolam Tosilate
The First People's Hospital of Lianyungang
Frailty
1 trial -
Remimazolam besylate
The First People's Hospital of Lianyungang
Remimazolam
1 trial -
Respiratory monitoring
The First People's Hospital of Lianyungang
Post-Op Complication
1 trial -
Rifaximin
The First People's Hospital of Lianyungang
Bacterial Overgrowth Syndrome Small Bowel
1 trial -
Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
Romiplostim N01
The First People's Hospital of Lianyungang
Primacy Immune Thrombocytopenia
1 trial -
Ropivacaine
The First People's Hospital of Lianyungang
Surgery
1 trial -
Routine Medication
The First People's Hospital of Lianyungang
Generalized Anxiety Disorder
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources